Be the first person to write a business review for Locus Pharmaceuticals, Inc.

Lonza Biologics plc, one of The Lonza Group's four biologic contracting manufacturing sites, is a leading contract manufacturer of monoclonal antibodies, recombinant proteins, and diagnostic monoclonal antibodies that are used to produce pharmaceuticals. Lonza Biologics conducts research and development on mammalian cell culturing involving cloning from non-animal origins. From its manufacturing facility near London, the company also supplies its products to other biotechnology companies.

Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.

MacroGenics Inc. company is developing therapeutic treatments for cancer, autoimmune disorders, and infectious diseases. The company is helping researchers from National Institutes of Health and two universities to develop a fully human monoclonal antibody (single disease-cell targeting protein) treatment for the deadly West Nile virus. MacroGenics is also in late development stages for another monoclonal antibody used to treat Type 1 diabetes (also known as juvenile diabetes); the diabetes treatment has received orphan drug status, an FDA designation for rare diseases. Other targeted ailments include cancer, arthritis, and multiple sclerosis.

Manhattan Pharmaceuticals, Inc. company was founded in 2001 and is based in New York, New York. Manhattan Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of pharmaceutical therapies in the United States. Its product candidates under development include Hedrin, a novel, non-insecticide treatment for pediculosis; and Topical PTH (1-34) for the treatment of psoriasis. Manhattan Pharmaceuticals has a joint venture agreement with Nordic Biotech Advisors ApS to develop and commercialize Hedrin.

MannKind Corporation was founded in 1991 and is headquartered in Valencia, California. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, a rapid-acting insulin that has completed phase 3 clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company's lead product candidates also include MKC1106-PP, which is in phase I clinical trial for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, non-small cell lung and prostate carcinomas, glioblastoma, and melanoma.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.